Inventor · disambiguated record
Hunter Paul Shunatona
Also filed as: SHUNATONA HUNTER · SHUNATONA HUNTER P · SHUNATONA HUNTER PAUL
27 granted patents·9 pending applications·110 citations·filing 2012–2025
95Inventor score
Files withNURIX THERAPEUTICS INC14FLEXUS BIOSCIENCES INC8BRISTOL MYERS SQUIBB CO5RAPT THERAPEUTICS INC4CELGENE CORP2
Top patents by PatentIndex Score
36 records- 0197US11530229B2Cyano cyclobutyl compounds for CBL-B inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Dec 20, 2022·12 cites·71 claims
- 0297US11464802B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Oct 11, 2022·14 cites·53 claims
- 0397US11401267B2Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Aug 2, 2022·11 cites·32 claims
- 0496US9643972B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2015·Granted May 9, 2017·15 cites·47 claims
- 0596US9598422B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2015·Granted Mar 21, 2017·21 cites·34 claims
- 0694US11951133B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Apr 9, 2024·2 cites·36 claims
- 0793US10106546B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2017·Granted Oct 23, 2018·6 cites·66 claims
- 0892US12485144B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·1 cites·40 claims
- 0992US12049471B2Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Jul 30, 2024·1 cites·16 claims
- 1091US11739101B2Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·3 cites·40 claims
- 1191US10246462B2Chemokine receptor modulators and uses thereofFLX BIO INC·Filed 2017·Granted Apr 2, 2019·10 cites·77 claims
- 1290US12234230B2Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Feb 25, 2025·1 cites·5 claims
- 1390US10179787B2Chemokine receptor modulators and uses thereofFLX BIO INC·Filed 2017·Granted Jan 15, 2019·5 cites·38 claims
- 1489US10533014B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2018·Granted Jan 14, 2020·3 cites·20 claims
- 1587US10604526B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2018·Granted Mar 31, 2020·2 cites·25 claims
- 1681US11046699B2Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic usesRAPT THERAPEUTICS INC·Filed 2019·Granted Jun 29, 2021·3 cites·46 claims
- 1781US2025136590A1Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1881US2024199620A1Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1980US2024409555A1Cyano cyclobutyl compounds for cbl-b inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2073US2024400587A1Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2172US2022127233A1Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparationBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 2272US2025320183A1Modulators of BCL6 as Ligand Directed DegradersCELGENE CORP·Filed 2025·Application pending·0 cites
- 2370US11919863B2Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparationBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 5, 2024·0 cites·17 claims
- 2469US12421195B2Amorphous and crystalline forms of IDO inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Sep 23, 2025·0 cites·12 claims
- 2568US12404239B2Modulators of BCL6 as ligand directed degradersCELGENE CORP·Filed 2023·Granted Sep 2, 2025·0 cites·10 claims
- 2668US12091426B2Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Sep 17, 2024·0 cites·29 claims
- 2767US2024025923A1Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2866US11932601B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2021·Granted Mar 19, 2024·0 cites·17 claims
- 2966US2020239480A1Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3063US11236049B2Amorphous and crystalline forms of IDO inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Feb 1, 2022·0 cites·4 claims
- 3161US11236048B2Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparationBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Feb 1, 2022·0 cites·16 claims
- 3257US11242319B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2015·Granted Feb 8, 2022·0 cites·23 claims
- 3356US10206893B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2017·Granted Feb 19, 2019·0 cites·23 claims
- 3450US2022324835A1Inhibitors of cbl-b and methods of use thereofNURIX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3542US10987322B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2015·Granted Apr 27, 2021·0 cites·21 claims
- 3639US9981977B2Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalystUNIV CALIFORNIA·Filed 2012·Granted May 29, 2018·0 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when Hunter Paul Shunatona files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →